Clinical Trial: Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants

U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07443436) titled 'Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants' on Feb. 11.

Brief Summary: Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).

The pathophysiology is unknown and seems to involve endoplasmic reticulum stress in type 2 alveolar epithelial cells.

Variable improvement in the prognosis of childhood and adult interstitial lung disease (ILD) associated with a variant of a SRG, initially reported to be lethal within months of diagnosis, has been observed since the consensual use of prednisone, azithro...